OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, OncoCyte currently has a consensus rating of “Hold” and an average target price of $4.06.

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $3.13 on Monday. The firm’s 50-day simple moving average is $3.08 and its 200-day simple moving average is $2.94. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The business had revenue of $0.10 million for the quarter.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.